@dolcevita
Re "Obviously it has to be proven in each application. But delivery and dosage is crucial."
Ok, so many would recognise this as the classic dolce back-track.
This involves you initially making some far-fetched claim. In this case it was this unsupported twaddle "Particularly as it is derisked. The science is in. It's proven."
After a few questions, you'll gradually water things down. So, on this occasion, we are finally given "Obviously it has to be proven in each application. But delivery and dosage is crucial.". And still not one supporting document to be seen.
So from "It's proven .." to "Obviously it has to be proven" ...
Unless someone keeps you on track, you just keep slipping in the blatantly misleading stuff. Hardly fair to those easily swayed "mums and dads" you've sworn to defend now is it?
- Forums
- ASX - By Stock
- MSB
- Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish
MSB
mesoblast limited
Add to My Watchlist
12.3%
!
$2.43
Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish, page-65
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
